Tests mirikizumab with or without tirzepatide in ulcerative colitis and excess weight

Trial details

Who runs it

Eli Lilly and Company

Trial code

NCT06937086EU 2024-520209-38-00

Record updated

4 November 2026

Original description

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.Read full original descriptionShow less

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.

Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

Inclusion: Have had an established diagnosis of UC for ≥3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC; Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline; Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer; Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]; Have overweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions:; hypertension; Type 2 Diabetes Mellitus (T2DM); dyslipidemia; obstructive sleep apnea, or; cardiovascular disease; Have an inadequate response to, loss of response to, or intolerance to at least 1 of the conventional medication: oral corticosteroids, oral azathioprine (AZA) or 6-mercaptopurine (6-MP), or oral 5-aminosalicylates (for example, mesalamine, sulfasalazine, olsalazine, and balsalazide) and/or who have an inadequate response to or a loss of response to, or are intolerant to advanced therapy for UC, defined as: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF) antibodies; anti-integrin antibodies, Janus kinase (JAK) inhibitors such as tofacitinib or upadacitinib, sphingosine 1-phosphate receptor 1inhibitors such as etrasimod or ozanimod, or anti-interleukin(IL)-12p40 antibodies, for example, ustekinumab.

Exclusion: Have had or will need bowel resection or intestinal or intra-abdominal surgery; Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening; Have a self-reported change in body weight greater than 5% (gain or reduction) within 3 months prior to screening; Have a current diagnosis of:; Crohn's disease; inflammatory bowel disease (IBD) unclassified (formerly known as indeterminate colitis), or; primary sclerosing cholangitis; Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM; Have a current or recent acute, active infection; Have evidence of toxic megacolon, or stricture or stenosis within the colon that cannot be traversed by a sigmoidoscope or colonoscope.

ClinicalTrials.gov NCT06937086 · EU CTIS 2024-520209-38-00